On the stock market since 2019, it operates in the world of health and science. It has 7,807 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 38% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 80% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $2.8B a year; the problem isn’t sales — it’s costs running above that number.
There is $14.8B in the vault; even if every debt were paid off, $14.6B would remain.
Over the last 12 months, company executives reported 10 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $1.1B against $2.8B in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, BNTX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BNTX has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.